← Back to Search


Retatrutide for Obesity

Phase 3
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants may be with or without type 2 diabetes (T2D) unless their hemoglobin A1c (HbA1c) is 10% or lower
Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD) as evidenced by at least one of the following: Coronary artery disease, Cerebrovascular disease, Peripheral arterial disease, Chronic kidney disease defined as: eGFR <45 millilitres/minute/1.73 meter squared (mL/min/1.73m^2) and UACR >30 milligram/gram (mg/g), eGFR <60 mL/min/1.73 m^2 and UACR >100 mg/g, or eGFR <75 mL/min/1.73 m^2 and UACR >300 mg/g (eGFR is calculated based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin c equation as determined by central lab)
Must not have
Participants have any of the following cardiovascular conditions ≤ 90 days prior to randomization: Myocardial infarction, Acute coronary syndrome, Stroke, or Coronary, peripheral, or carotid artery arterial revascularization procedure, Have acute decompensated heart failure requiring hospitalization, Have New York Heart Association (NYHA) Classification Class IV heart failure at screening
Participants have Type 1 Diabetes or history of diabetic ketoacidosis
Screening 3 weeks
Treatment Varies
Follow Up randomization up to study completion (approximate 248 weeks)
Awards & highlights


This trial aims to see if retatrutide can reduce serious heart problems and stop kidney function from getting worse in adults with a high body mass index and heart or kidney disease.

Who is the study for?
This trial is for adults with obesity (BMI of 27 or higher) who also have heart disease and/or chronic kidney disease. It's not specified who can't join, but typically those with conditions that could interfere with the study or pose a risk to their health are excluded.Check my eligibility
What is being tested?
The TRIUMPH-OUTCOMES trial is testing if retatrutide, given once weekly, can reduce serious heart complications or slow down kidney function decline in obese individuals compared to a placebo.See study design
What are the potential side effects?
While specific side effects aren't listed here, drugs like retatrutide often cause gastrointestinal issues such as nausea and diarrhea. They may also affect blood sugar levels and potentially cause allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My HbA1c level is 10% or lower, with or without type 2 diabetes.
I have heart disease, stroke history, or kidney disease with specific test results.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I haven't had a heart attack, stroke, or heart failure in the last 3 months.
I have Type 1 Diabetes or have had diabetic ketoacidosis.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~randomization up to study completion (approximate 248 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and randomization up to study completion (approximate 248 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death
Time to First Occurrence of Composite Endpoints
Secondary outcome measures
Percentage change from Baseline in Albuminuria urinary albumin/creatinine ratio (UACR) in Participants with UACR ≥30 mg/g (0.03 mg/mg) at baseline
Time to First Occurrence of Composite Endpoint of CV death, or hospitalization or urgent visit due to HF
Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events (MACE-3)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RetatrutideExperimental Treatment1 Intervention
Participants will receive escalated doses of retatrutide administered subcutaneously (SC) up to a maximum tolerated dose.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive matching placebo administered SC.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,629 Previous Clinical Trials
3,208,110 Total Patients Enrolled
57 Trials studying Obesity
41,825 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,351 Previous Clinical Trials
406,476 Total Patients Enrolled
40 Trials studying Obesity
21,544 Patients Enrolled for Obesity
~6667 spots leftby Feb 2029